Preformulation study of the inclusion complex irbesartan-β-cyclodextrin

AAPS PharmSciTech

Volumn 10, Issue 1, 2009, Pages 276-281

  Hirlekar, Rajashree ^a   Kadam, Vilasrao ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

cyclodextrin; Dissolution; Inclusion complex; Irbesartan; Solubility

Indexed keywords

ALCOHOL; BETA CYCLODEXTRIN; IRBESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA CYCLODEXTRIN DERIVATIVE; BIPHENYL DERIVATIVE; DRUG CARRIER; TETRAZOLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STABILITY; EVAPORATION; INFRARED SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; STOICHIOMETRY; X RAY DIFFRACTION; CHEMISTRY; KINETICS; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICS; SOLUBILITY; SURFACE PROPERTY; X RAY CRYSTALLOGRAPHY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BETA-CYCLODEXTRINS; BIPHENYL COMPOUNDS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; TETRAZOLES;

EID: 67549115862     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9206-5     Document Type: Article

References (13)

1. S. C. Sweetman. Martindale - The Complete Drug Reference, Pharmaceutical, London, 2005.
2. H. G. Pouleur. Clinical overview of Irbesartan: A new angiotensin II receptor antagonist. Am. J. Hypertens. 10:318-324 (1997).
3. G. Chawla, and A. K. Bansal. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur. J. Pharm. Sci. 32:45-57 (2007).
4. T. Loftsson, M. E. Brewster, and M. Masson. Role of cyclodextrins in improving oral drug delivery. Am. J. Drug Deliv. 24:261-274 (2004).
5. E. M. Martin Del Valle. Cyclodextrins and their uses: A review. Process. Biochem. 39:1033:1046 (2004).
6. R. L. Carrier, L. A. Miller, and I. Ahmed. The utility of cyclodextrins for enhancing oral bioavailability. J. Control. Release. 123:78-99 (2007).
7. T. Higuchi, and K. A. Connors. Phase solubility diagram. Adv. Anal. Chem. Instr. 4:117-212 (1965).
8. N. Li, Y. H. Zhang, Y. N. Wu, X. L. Xiong, and Y. H. Zhang. Inclusion complex of trimethoprim with β-cyclodextrin. J. Pharm. Biomed. Anal. 39:824-829 (2005).
9. G. Zingone, and F. Rubessa. Preformulation study of the inclusion complex warfarin-β-cyclodextrin. Int. J. Pharm. 291:3-10 (2005).
10. C. M. Fernandes, M. T. Vieira, and F. J. B. Veiga. Physicochemical characterization and in vitro dissolution behavior of nicardipine-β-cyclodextrins inclusion compounds. Eur. J. Pharm. Sci. 15:79-88 (2002).
11. L. Liu, and S. Zhu. Preparation and characterization of inclusion complexes of prazosin hydrochloride with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. J. Pharm. Biomed. Anal. 40:122-127 (2006).
12. J. B. Chao, and B. T. Zhang. Preparation and study on the solid inclusion complex of cloxacillin sodium with β-cyclodextrin. Spectrochim. Acta, Part A. 68:108-112 (2007).
13. H. J. Schneider, F. Hacket, and V. Rudiger. NMR studies of cyclodextrins and cyclodextrin complexes. Chem. Rev. 98:1755-1785 (1998).